Browse 104 Kidney Cancer Medical Studies Across 425 Cities
14 Phase 3 Trial · 1747 Kidney Cancer Clinics
What Are Kidney Cancer Clinical Trials?
This cancer is the growth of abnormal cells in the kidney. A malignant or cancerous cell can rapidly spread to other organs and tissues, and this process is known as metastasis. Kidney cancer patients experience multiple signs and symptoms, like blood in urine, high blood pressure, and flank pain, among other symptoms.
Why Is Kidney Cancer Being Studied Through Clinical Trials?
Around 79,000 kidney cancer cases are diagnosed every year, and an estimated 13,920 individuals don't survive. On average, the patients diagnosed with kidney cancer are around 65.
Around two-thirds of individuals are diagnosed in cases where cancer is only present in the kidney. Among this group, there is a 93% five years survival rate. In cases where cancer has spread to other organs and surrounding tissues, there is a 71% five years survival rate.
This cancer is only treated if it is diagnosed at the early stages.
What Are The Types of Treatments Available For Kidney Cancer?
The treatment of kidney cancer depends on the grade and stage of the tumor, along with the overall health and age of the patient. The treatment options include:
What Are Some Recent Breakthrough Clinical Trials For Kidney Cancer?
There have been several landmark studies involving Kidney Cancer in recent years. Some of the most recent studies are:
2022: A clinical trial proved the increase in survival rate among kidney disease patients through immune checkpoint inhibitors. The researchers found an overall survival benefit using FDA-approved nivolumab in comparison to everolimus, which is the standard kidney cancer treatment. While immunotherapy has been proven to have a positive impact on kidney cancer survival but these results have shown drastic survival benefits. This is an opportunity to modify and improve clinical practice and procedures.
2021: Immunotherapy combination has been found to enhance the survival outcome in severe kidney cancer patients. The initial results of the CheckMate -9ER clinical trial phase III showed that the immunotherapy agent mixed with tyrosine kinase inhibitor drastically improved the survival rate and decreased the fatality risk compared to the single agent treatment.
Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Kidney Cancer Clinical Trials Research?
Kidney Cancer Association: It is a global community empowering and serving kidney cancer patients and leading change through education, research, and advocacy. This association promotes and funds scientific advances through its grant program and annual research symposiums. They are dedicated to becoming the leaders in finding a kidney cancer cure.
National Kidney Foundation: This foundation is among the pioneers of scientific innovation and research for kidney diseases and disorders. They are dedicated to improving the lives of kidney cancer and kidney disease patients through change, education, and action.